TOP > 外国特許検索 > BIOMARKERS FOR DETERMINING CANCER SUCH AS PANCREATIC CANCER

BIOMARKERS FOR DETERMINING CANCER SUCH AS PANCREATIC CANCER NEW

外国特許コード F190009931
整理番号 (S2018-0241-N0)
掲載日 2019年10月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP047362
国際公開番号 WO 2019131552
国際出願日 平成30年12月21日(2018.12.21)
国際公開日 令和元年7月4日(2019.7.4)
優先権データ
  • 特願2017-251593 (2017.12.27) JP
発明の名称 (英語) BIOMARKERS FOR DETERMINING CANCER SUCH AS PANCREATIC CANCER NEW
発明の概要(英語) The present invention addresses the problem of providing a method for accurately determining the presence or absence of, or the risk for developing, one or more types of cancer selected from the group consisting of pancreatic cancer, gastric cancer, colon cancer, duodenal cancer, and biliary cancer (preferably pancreatic cancer, and more preferably early-stage pancreatic cancer); and biomarkers for the determination thereof. In the present invention, one or more substances selected from the groups of substances listed in [Group A] and [Group B] below are used as biomarkers for accurate determination of the presence or absence of, or the risk for developing, pancreatic cancer, including early-stage pancreatic cancer, as well as gastric cancer, colon cancer, duodenal cancer, and biliary cancer. [Group A] partial peptides ofAPOA4, partial peptides of APOA1, partial peptides of TTHY, partial peptides of Q5VY30, partial peptides of H0YAC1, partial peptides of BTD, APOA4, APOA1, TTHY, Q5VY30, H0YAC1, and BTD; [Group B] partial peptides of ITIH3, and ITIH3
従来技術、競合技術の概要(英語) BACKGROUND ART
The cancer is a leading cause of death which occupies a higher percentage, the situation continues for a long. The development of various anti-cancer agent and has been so far, such as an inhibitor of the checkpoint, the previous anti-cancer agent more effective but are also in practical use, the degree of anticancer activity obtained individual difference and large due to the difference types of cancers, the cancer is still continues and a threat for the human. However, if the cancer is found at an early stage, the treatment can be started at an early stage, cancer death rate can be greatly reduced. Therefore, a more accurate or more various, the determination of cancer, diagnosis methods, in particular, the determination of early cancer, the diagnosis method has been developed.
Incidentally, among the cancer, pancreatic cancer is one of a refractory cancer, effective therapy other than the surgery is not established. Pancreatic cancer is a major refractory cancer and one of the factors, the pancreas is the back side of the stomach, that is, and the depth of the body, even if not of the appearance of symptoms of cancer, early detection is that it is very difficult and can be referred to. Indeed, pancreatic cancer is about 9% and 5 year survival rate of the poor prognosis significantly, pancreatic cancer at an early stage (the stage I) of the annual rate of 41% and 5 may be relatively poor prognosis Z reside. In this way, early detection of pancreatic cancer in, and is particularly important to early treatment, pancreatic cancer is detected early than the current long, pancreatic cancer patient 5 of the greatly-year survival rate can be dramatically enhanced or can be expected.
Pancreatic cancer as a diagnostic method, serum tumor marker can be used known CA19-9 respectively. In addition, in recent years, in the diagnosis of pancreatic cancer, the helical CT, magnetic resonance imaging (MRI) apparatus, an endoscopic ultrasound (EUS) inspection method and the like is used. However, any of these diagnostic method, the diagnosis of pancreatic cancer not sufficient as a method, in particular, early pancreatic cancer diagnosis was quite unsatisfactory as a method.
Pancreatic cancer for diagnosis of early stage, to Patent Document 1, labeled with a radionuclide (RGDfK) peptide c, the step of administering to a mammal, and, in the pancreas of the mammal after administration of radioactive nuclides comprising the steps of detecting, the early detection of pancreatic cancer has been disclosed a method. However, in this method, the peptide is labeled with a radionuclide is required careful handling, the utility is not high. On the other hand, the present inventors have so far, is present in the plasma biomarkers insulin-like growth factor-binding protein(IGFBP) 2 and IGFBP 3 is, in the early detection of pancreatic cancer are found to be useful (non-patent document 1). However, a particular substance of the present invention is selected from the group consisting of 2 1 or one or more materials, pancreatic cancer, stomach cancer, colon cancer, biliary cancer and duodenum cancer is selected from the group consisting of one or more one or 1 2 can be determined whether or not there is the risk of the cancer biomarkers in, especially, early pancreatic cancer biomarker can be determined whether or not there is to be at risk for, has not been known until now.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
  • 発明者(英語)
  • OHTSUKI, Sumio
  • ITO, Shingo
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接ご連絡ください。

PAGE TOP

close
close
close
close
close
close